Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00053716 |
Recruitment Status : Unknown
Verified March 2004 by Endovasc.
Recruitment status was: Recruiting
First Posted : February 6, 2003
Last Update Posted : March 7, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Peripheral Vascular Disease | Drug: Liprostin [liposomal Prostaglandin E1] | Phase 2 |
PAOD results in a decrease in arterial blood flow to the lower limb and feet with symptoms that can include, pain at rest, a numbing sensation in limb or feet, limited ability to walk before pain occurs. PAOD can occur along with diabetic ulcers.
Proposed treatment will be given at a medical center with an overnight hospital stay. Treatment includes angioplasty to open up one or two occluded arteries in a lower limb plus a drug (Liprostin) a special formulation of liposomal Prostaglandin E1,or PGE1, a natural occuring vasoactive hormone). Drug treatment is given twice to each artery to be treated, just before and after angioplasty. When angioplasty procedure is completed, a 12 hour intravenous infusion of Liprostin is given to complete the treatment procedure.
A total of 12 PAOD subjects will be enrolled in a single center: Memorial Hermann Hospital, Houston, TX.
Study will begin in February, 2003 with the last (12th) subject to be enrolled, likely by August, 20
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 12 participants |
Allocation: | Non-Randomized |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II, Single Center, Non-Controlled, Open-Label Study of Liposomal Prostaglandin E1 (Liprostin) as Adjunct Therapy With Lower Limb Angioplasty in Patients With Ischemic and Non-Ischemic Peripheral Arterial Occlusive Disease |
Study Start Date : | February 2003 |
Study Completion Date : | August 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subjects, 18 years and older
- Diagnosis of Peripheral Arterial Occlusive Disease [PAOD]
- Subject is a candidate for immediate angioplasty of the lower limb
- Subject must complete 2 treadmill tests at Screen in which walking distance is limited by PAOD and not due to angina or fatigue
Exclusion Criteria:
- Lower limb peripheral re-vascularization procedures in past 3 months
- History of myocardial infarction in the past 6 months
- Malignant disease, uncontrolled hypertension or Class III heart failure
- Aortic occlusion, thrombosed popliteal aneurysm, severe hemorrhagic disorder, or a long iliac occlusion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00053716
United States, Texas | |
Memorial Hermann Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Catey Carter, RN 713-500-6550 catharine.v.carter@uth.tmc.edu | |
Contact: Carol J Underwood, RN 713-500-6563 carol.j.underwood@uth.tmc.edu | |
Principal Investigator: Richard W. Smalling, M.D., Ph.D |
ClinicalTrials.gov Identifier: | NCT00053716 |
Other Study ID Numbers: |
EV 2002-05 Limb Arterial Disease Study |
First Posted: | February 6, 2003 Key Record Dates |
Last Update Posted: | March 7, 2007 |
Last Verified: | March 2004 |
Angioplasty & PGE1 Treatment of Peripheral Vascular Disease |
Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Arterial Occlusive Diseases Cardiovascular Diseases Atherosclerosis |
Arteriosclerosis Alprostadil Platelet Aggregation Inhibitors Vasodilator Agents Urological Agents |